Latest stories on KYMR
KYMR Maintained by Morgan Stanley -- Price Target Raised to $146
GuruFocus63 · neutralanalyst
Kymera Therapeutics price target raised to $146 from $135 at Morgan Stanley
The Fly64 · neutralanalyst
Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
GlobeNewswire50 · neutralgeneral
Kymera: Over-Hyped, Or Developing Next Dupixent? We'll Find Out Very Soon
Seeking Alpha55 · neutralproduct/pr
Raymond James initiates Kymera Therapeutics stock coverage with outperform rating
Investing.com Analyst Ratings63 · neutralanalyst
Kymera Therapeutics initiated with an Outperform at Raymond James
The Fly63 · neutralanalyst
Citi adds ‘upside 90-day catalyst watch’ on Kymera Therapeutics
The Fly56 · neutralanalyst
Citi raises Kymera Therapeutics stock price target on drug potential
Investing.com Analyst Ratings61 · neutralanalyst
Kymera Therapeutics price target raised to $150 from $135 at Citi
The Fly61 · neutralanalyst
B.Riley reiterates Kymera Therapeutics stock rating on new trial data
Investing.com Analyst Ratings56 · neutralanalyst
Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm
PR Newswire42 · neutralgeneral
Kymera Therapeutics placed on ‘Positive Catalyst Watch’ at JPMorgan
The Fly63 · neutralanalyst
Goldman Sachs resumes Kymera Therapeutics stock coverage
Investing.com Analyst Ratings56 · neutralanalyst
Kymera Therapeutics resumed with Early-Stage Biotech at Goldman Sachs
The Fly56 · neutralgeneral
Stifel raises Kymera Therapeutics price target on drug trial outlook
Investing.com Analyst Ratings61 · neutralanalyst
Kymera Therapeutics price target raised to $152 from $132 at Stifel
The Fly61 · neutralanalyst
Kymera Therapeutics management to meet with Piper Sandler
The Fly56 · neutralgeneral
Kymera Therapeutics, Inc. (KYMR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha56 · neutralproduct/pr
Kymera Therapeutics price target raised to $144 from $123 at BofA
The Fly61 · neutralanalyst
BofA raises Kymera Therapeutics price target on trial progress
Investing.com Analyst Ratings61 · neutralanalyst
Kymera Therapeutics, Inc. (KYMR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Seeking Alpha56 · neutralgeneral
Wolfe upgrades Kymera Therapeutics to Outperform on potential upside
The Fly61 · neutralanalyst
Kymera Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research
The Fly61 · neutralanalyst
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
GlobeNewswire56 · neutralgeneral
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
StockTitan56 · neutralgeneral